Ahead of CPHI Milan, EPM spoke to Hayley Crowe, executive vice president and general manager of Ecolab's Global Life Sciences sector, to discuss the company's approach to addressing the growing demand of cell and gene therapies (C>s) and supply chain challenges, while maintaining its sustainability goals.
Q. How are you innovating to meet the growing demand for personalised medicine and cell and gene therapies?
New modalities, like cell and gene therapies (C>s) currently focus predominantly on targeting rare diseases, which typically have small patient populations. For many of these patients, there are no other effective treatment options, and the success or failure of a C> can be life-altering. Inconsistent product quality could lead to treatment failure or lead to adverse effects on patient health. As a result, ensuring process and scale-up consistency has become increasingly critical for these new complex therapies.